FRANKLIN LAKES, New Jersey | January 19, 2026 — Becton, Dickinson and Company (BD) announced that the U.S. Food and Drug Administration has granted 510(k) clearance for its EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a next-generation, multi-modality vacuum-assisted biopsy device designed to enable minimally invasive breast tissue sampling across stereotactic (X-ray), ultrasound, and MRI guidance. The clearance supports BD’s planned commercial launch in early 2026 and expands access to FDA-cleared diagnostic technologies for breast cancer detection and care.
Science Significance
From a scientific and clinical technology perspective, the EnCor EnCompass system represents an evolution in image-guided percutaneous breast biopsy, a technique that has largely replaced open surgical biopsy for initial diagnosis of suspicious breast lesions. Vacuum-assisted biopsy systems are designed to obtain larger, contiguous tissue samples compared with traditional core needle biopsy, improving diagnostic confidence while reducing sampling error. The EnCor EnCompass builds on this foundation with adjustable vacuum control, multiple gauge options (12G, 10G, and 7G), and a 360-degree rotating aperture, enabling clinicians to tailor tissue acquisition in real time. By supporting high-volume tissue sampling and potential complete lesion excision, the system aligns with ongoing scientific efforts to improve accuracy in diagnosing conditions such as ductal carcinoma in situ (DCIS), atypical hyperplasia, and other high-risk breast lesions.
Regulatory Significance
The FDA’s 510(k) clearance confirms that the EnCor EnCompass system is substantially equivalent to legally marketed predicate devices, meeting U.S. regulatory standards for safety, performance, and usability. For the cGxP community, this clearance highlights the importance of design controls, risk management, and verification testing under the FDA’s Quality System Regulation (QSR). Multi-modality capability introduces additional regulatory complexity, as devices must demonstrate consistent performance across different imaging environments. The clearance underscores FDA’s continued acceptance of advanced vacuum-assisted biopsy technologies as part of standard diagnostic workflows in breast care.
Business Significance
Advertisement
Commercially, the clearance strengthens BD’s breast health and interventional diagnostics portfolio, positioning the company to compete in a global market increasingly focused on minimally invasive diagnostic solutions. The ability to offer a single console compatible with multiple imaging modalities addresses a long-standing operational challenge for hospitals and imaging centers, potentially reducing capital equipment costs and training burdens. Strategically, the EnCor EnCompass launch supports BD’s broader MedTech growth strategy by leveraging its established footprint in diagnostics, interventional procedures, and regulated medical devices, while reinforcing its reputation for delivering clinically validated, FDA-cleared technologies.
Patients’ Significance
For patients, the EnCor EnCompass system has the potential to improve both clinical outcomes and the diagnostic experience. Minimally invasive vacuum-assisted biopsy procedures are associated with shorter procedure times, reduced scarring, lower complication rates, and faster recovery compared with surgical biopsy. Enhanced tissue yield can reduce the likelihood of repeat biopsies, sparing patients additional procedures and anxiety. By enabling accurate diagnosis — and in some cases complete removal — of benign or high-risk lesions through a small incision, the technology supports earlier answers and more patient-centered care in breast cancer evaluation.
Policy Significance
At a policy level, the clearance reflects broader healthcare system priorities focused on early detection, minimally invasive diagnostics, and value-based care. Technologies that reduce unnecessary surgery and associated healthcare costs align with public health objectives aimed at improving efficiency without compromising diagnostic accuracy. The FDA’s continued clearance of advanced biopsy systems also reinforces regulatory support for incremental innovation within established diagnostic pathways, encouraging manufacturers to invest in usability, workflow efficiency, and patient safety enhancements.
The FDA clearance of BD’s EnCor EnCompass™ Breast Biopsy and Tissue Removal System represents a meaningful advancement in regulated medical technology for breast cancer diagnosis. By combining multi-modality compatibility, high-volume vacuum-assisted sampling, and workflow-focused design, the system addresses key scientific, regulatory, and clinical needs in modern breast care. As it enters the market in early 2026, EnCor EnCompass exemplifies how MedTech innovation, FDA oversight, and patient-centric design can converge to support earlier, more precise, and less invasive cancer diagnostics — a core priority for the cGxP-focused healthcare ecosystem.
Source: Becton, Dickinson and Company (BD) press release
